|
|
Targeted in vivo perturbation for dissecting tissue immune responses |
| 2U19AI128949-06 |
|
NIAID |
2022 |
|
|
Clinical Core |
| 2U19AI128949-06 |
|
NIAID |
2022 |
|
|
Project 2: T Cell Costimulation: Induction and Regulation of Autoimmunity |
| 5P01AI056299-19 |
|
NIAID |
2022 |
|
|
Project 3 - Mechanisms of DNRAb-mediated damage to the fetal brain |
| 5P01AI073693-13 |
|
NIAID |
2022 |
|
|
Innate Immune Response to S. aureus Biofilm |
| 5P01AI083211-14 |
|
NIAID |
2022 |
|
|
Persistent Post-Viral State of Bacterial Pneumonia Susceptibility and Severity in Down Syndrome |
| 5R01AI141662-04 |
|
NIAID |
2022 |
|
|
The effectiveness of RSV immunoprophylaxis on the short- and long- term respiratory morbidity in children with Down syndrome |
| 5R01AI143710-04 |
|
NIAID |
2022 |
|
|
Dissecting the impact of interferon hypersensitivity on mouse models of Down syndrome |
| 5R01AI145988-04 |
|
NIAID |
2022 |
|
|
Mediator kinases as interferon antagonists in Down Syndrome |
| 5R01AI156739-03 |
|
NIAID |
2022 |
|
|
The Impact of Maternal CMV Infection on Birth Outcomes |
| 5R03AI151426-02 |
|
NIAID |
2022 |